Leonardo Signori

Florence, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera.

Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera.

Journal: Blood neoplasia
Published: February 09, 2026

Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.

Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.

Journal: Blood cancer journal
Published: December 16, 2025

APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications.

APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications.

Journal: HemaSphere
Published: September 15, 2025

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and mature plasmacytoid dendritic cell proliferation (MPDCP): the same cell of origin from a clonal haematopoiesis of indeterminate potential (CHIP)?

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and mature plasmacytoid dendritic cell proliferation (MPDCP): the same cell of origin from a clonal haematopoiesis of indeterminate potential (CHIP)?

Journal: Histopathology
Published: July 29, 2025

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML.

Journal: Blood cancer journal
Published: December 17, 2024

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting.

Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting.

Journal: Haematologica
Published: June 10, 2024

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.

Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia.

Journal: American journal of hematology
Published: April 29, 2024

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.

Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib.

Journal: Haematologica
Published: January 30, 2024

The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.

The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.

Journal: American journal of hematology
Published: September 14, 2023

Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.

Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.

Journal: Haematologica
Published: March 24, 2023

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.

Journal: Journal of clinical medicine
Published: February 23, 2021

Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category.

Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category.

Journal: Cancers
Published: September 30, 2020
Showing 1-12 of 12

Last Updated: 09/26/2026